Document resource
Background Single cell resolution at massive scale has become critical for advancing biomedical research, offering unprecedented insights into cellular heterogeneity, tissue architecture, and disease mechanisms. Landmark initiatives such as the Human Cell Atlas and the Billion Cells Project (Chan Zuckerberg Initiative) are driving an urgent demand for higher-throughput single cell technologies. Simultaneously, there is increasing need for platforms that can accommodate a wide range of clinically relevant sample types including blood, fresh or frozen tissues, and formalin fixed paraffin embedded (FFPE) blocks, while enabling efficient sample collection, transport, storage, and batch processing. GEM-X Flex is currently the only platform that addresses all these demands, and enables profiling of up to 320,000 cells per GEM-X microfluidic chip lane with the capability of 16-sample multiplexing. Building on this robust foundation, we are excited to introduce GEM-X Flex v2, a major upgrade featuring enhanced sensitivity and dramatically expanded multiplexing capabilities that enables simultaneous processing of up to 384 multiplexed samples and profiling of up to 1 million cells per lane.Methods To demonstrate the expanded multiplexing capacity of GEM-X Flex v2 along with a streamlined FFPE tissue dissociation workflow, we processed 96 FFPE sections derived from a variety of human tissues in one 96-well plate. The resulting nuclei were processed using the GEM-X Flex v2 workflow with 96 unique multiplexing barcodes. Additionally, we profiled cancer cell responses to a panel of small-molecule compounds across multiple time points using a 384-plex configuration. In both demonstrated cases, following hybridization with probes and unique multiplexing barcodes, nuclei or cells from each sample were pooled, washed, and loaded onto one single GEM lane, targeting recovery of approximately 1 million nuclei or cells.Results GEM-X Flex v2 successfully profiled 96 FFPE samples in a single GEM lane, enabling the identification of distinct cell types and markers across multiple tissue types. Utilizing a 384-plex configuration, we simultaneously captured the dynamic activation of diverse signaling pathways in response to a wide array of anti-cancer compounds, revealing mechanistic insights with the potential to support cancer therapy development.Conclusions Our study highlights the power of the GEM-X Flex v2 workflow with two high-throughput applications for both clinical sample profiling and anti-cancer drug mechanism studies. With improved sensitivity, higher sample throughput, and reduced cost, GEM-X Flex v2 delivers higher-quality data and improved efficiency, making it a powerful, versatile platform for large-scale single cell transcriptomic studies in both academic and biopharma settings.